UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2015-07, Vol.314 (2), p.151

2015

Volltextzugriff (PDF)

Novel Approaches Towards a Functional Cure of HIV/AIDS

Drugs (New York, N.Y.), 2020-06, Vol.80 (9), p.859-868

2020

Volltextzugriff (PDF)

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

The New England journal of medicine, 2015-01, Vol.372 (3), p.211-221

2015

Volltextzugriff (PDF)

Correction to: Novel Approaches Towards a Functional Cure of HIV/AIDS

Drugs (New York, N.Y.), 2020-06, Vol.80 (9), p.869-869

2020

Volltextzugriff (PDF)

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors

European journal of heart failure, 2015-10, Vol.17 (10), p.1057-1065

2015

Volltextzugriff (PDF)

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia

Kidney international, 2015-12, Vol.88 (6), p.1427-1433

2015

Volltextzugriff (PDF)

Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals

Fertility and sterility, 2024-01, Vol.121 (1), p.95-106

2024

Volltextzugriff (PDF)

Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors

Kidney international, 2016-09, Vol.90 (3), p.696-704

2016

Volltextzugriff (PDF)

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial

JAMA : the journal of the American Medical Association, 2004-11, Vol.292 (18), p.2217

2004

Volltextzugriff (PDF)

Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia

Journal of cardiovascular pharmacology and therapeutics, 2016-09, Vol.21 (5), p.456-465

2016

Volltextzugriff (PDF)

Food and Drug Administration Public Workshop Summary—Addressing Challenges in Inhaled Antifungal Drug Development

Clinical infectious diseases, 2024-06, Vol.78 (6), p.1564-1570

2024

Volltextzugriff (PDF)

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics

Journal of hypertension, 2017-05, Vol.35 Suppl 1 (Supplement 1), p.S57-S63

2017

Volltextzugriff (PDF)

OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD

Journal of hypertension, 2016-09, Vol.34 Suppl 1 - ISH 2016 Abstract Book (Supplement 1), p.e229-e229

2016

Volltextzugriff (PDF)

SO010PATIROMER PROTECTED AGAINST RECURRENT HYPERKALEMIA FOR UP TO 52 WEEKS IN PATIENTS WITH DIABETIC KIDNEY DISEASE (DKD) RECEIVING COMBINED RAAS INHIBITOR THERAPY

Nephrology, dialysis, transplantation, 2016-05, Vol.31 (suppl_1), p.i4-i4

2016

Volltextzugriff (PDF)

Abstract 14271: Patiromer Controls Hyperkalemia in Resistant Hypertensive Patients on RAASi, With Diabetic Kidney Disease

Circulation (New York, N.Y.), 2015-11, Vol.132 (Suppl_3 Suppl 3), p.A14271-A14271

2015

Volltextzugriff (PDF)

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease

ESC Heart Failure, 2018-06, Vol.5 (3), p.257-266

2018

Volltextzugriff (PDF)

FO020A PHASE 2 OPEN-LABEL SINGLE-ARM STUDY TO ASSESS THE EFFECT OF SNF472 ON WOUND HEALING IN CALCIPHYLAXIS (CALCIFIC UREMIC ARTERIOLOPATHY) PATIENTS

Nephrology, dialysis, transplantation, 2018-05, Vol.33 (suppl_1), p.i9-i9

2018

Volltextzugriff (PDF)

Long‐term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin‐converting enzymes/angiotensin receptor blockers: results from AMETHYST‐DN

ESC Heart Failure, 2018-08, Vol.5 (4), p.592-602

2018

Volltextzugriff (PDF)

1-YEAR SAFETY AND EFFICACY OF PATIROMER FOR HYPERKALEMIA IN HEART FAILURE PATIENTS WITH CHRONIC KIDNEY DISEASE ON RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS

Journal of the American College of Cardiology, 2015-03, Vol.65 (10), p.A855-A855

2015

Volltextzugriff (PDF)

Abstract P602: Patiromer Decreased Aldosterone, Urine Albumin/Creatinine Ratio, and Blood Pressure in Patients with Chronic Kidney Disease and Hyperkalemia on RAAS Inhibitors: Results from OPAL-HK

Hypertension (Dallas, Tex. 1979), 2015-09, Vol.66 (suppl_1)

2015

Volltextzugriff (PDF)

OS 19-03 TREATMENT WITH PATIROMER RESULTED IN DECREASES IN ALDOSTERONE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERKALEMIA ON RAAS INHIBITORS: RESULTS FROM OPAL-HK

Journal of hypertension, 2016-09, Vol.34 Suppl 1 - ISH 2016 Abstract Book (Supplement 1), p.e228-e229

2016

Volltextzugriff (PDF)

New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval

International journal of cardiology, 2016-08, Vol.216, p.46-51

2016

Volltextzugriff (PDF)

SuO019PATIROMER LOWERED SERUM POTASSIUM FOR UP TO 1 YEAR IN HYPERKALEMIC PATIENTS WITH DIABETES AND ADVANCED KIDNEY DISEASE ON RAAS INHIBITORS

Nephrology, dialysis, transplantation, 2015-05, Vol.30 (suppl_3), p.iii51-iii52

2015

Volltextzugriff (PDF)

Patiromer lowers serum potassium and prevents recurrent hyperkalemia in patients with heart failure and CKD when treated with RAAS inhibitors: Results from OPAL-HK

Heart & lung, 2015-11, Vol.44 (6), p.550-550

2015

Volltextzugriff (PDF)

Patiromer Reduces Serum K+ in Hyperkalemic Patients with HF and CKD on RAAS Inhibitors: Results from OPAL-HK and AMETHYST-DN

Journal of cardiac failure, 2015-08, Vol.21 (8), p.S107-S108

2015

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(49)
Reviews
(2)

Sprache

Englisch
(51)

Erscheinungsjahr

n.n

Thema

Humans
(23)
Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Female
(15)
Male
(12)
Middle Aged
(10)
Cardiovascular
(9)
Aged
(8)
Hyperkalemia - Drug Therapy
(8)
Potassium - Blood
(8)
Cardiovascular System & Cardiology
(7)
Adult
(6)
Cardiac & Cardiovascular Systems
(6)
Hyperkalemia - Blood
(6)
Angiotensin-Converting Enzyme Inhibitors - Therapeutic Use
(5)
Chronic Kidney Disease
(5)
Hyperkalemia
(5)
Hyperkalemia - Etiology
(5)
Patiromer
(5)
Polymers - Therapeutic Use
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial

Novel Approaches Towards a Functional Cure of HIV/AIDS

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

Correction to: Novel Approaches Towards a Functional Cure of HIV/AIDS

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia

Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals

Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial

Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia

Food and Drug Administration Public Workshop Summary—Addressing Challenges in Inhaled Antifungal Drug Development

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics

OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD

SO010PATIROMER PROTECTED AGAINST RECURRENT HYPERKALEMIA FOR UP TO 52 WEEKS IN PATIENTS WITH DIABETIC KIDNEY DISEASE (DKD) RECEIVING COMBINED RAAS INHIBITOR THERAPY

Abstract 14271: Patiromer Controls Hyperkalemia in Resistant Hypertensive Patients on RAASi, With Diabetic Kidney Disease

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease

FO020A PHASE 2 OPEN-LABEL SINGLE-ARM STUDY TO ASSESS THE EFFECT OF SNF472 ON WOUND HEALING IN CALCIPHYLAXIS (CALCIFIC UREMIC ARTERIOLOPATHY) PATIENTS

Long‐term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin‐converting enzymes/angiotensin receptor blockers: results from AMETHYST‐DN

1-YEAR SAFETY AND EFFICACY OF PATIROMER FOR HYPERKALEMIA IN HEART FAILURE PATIENTS WITH CHRONIC KIDNEY DISEASE ON RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS

Abstract P602: Patiromer Decreased Aldosterone, Urine Albumin/Creatinine Ratio, and Blood Pressure in Patients with Chronic Kidney Disease and Hyperkalemia on RAAS Inhibitors: Results from OPAL-HK

OS 19-03 TREATMENT WITH PATIROMER RESULTED IN DECREASES IN ALDOSTERONE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERKALEMIA ON RAAS INHIBITORS: RESULTS FROM OPAL-HK

New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval

SuO019PATIROMER LOWERED SERUM POTASSIUM FOR UP TO 1 YEAR IN HYPERKALEMIC PATIENTS WITH DIABETES AND ADVANCED KIDNEY DISEASE ON RAAS INHIBITORS

Patiromer lowers serum potassium and prevents recurrent hyperkalemia in patients with heart failure and CKD when treated with RAAS inhibitors: Results from OPAL-HK

Patiromer Reduces Serum K+ in Hyperkalemic Patients with HF and CKD on RAAS Inhibitors: Results from OPAL-HK and AMETHYST-DN

Suchergebnisse filtern